资源描述：
《单磷酸阿糖腺苷联合开喉剑喷雾剂治疗疱疹性咽峡炎50例疗效观察》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、单磷酸阿糖腺昔联合开喉剑喷雾剂治疗疱疹性咽峡炎50例疗效观察摘要目的：观察和评估单磷酸阿糖腺昔联合开喉剑喷雾剂治疗疱疹性咽峡炎患儿的疗效。方法：选取我院2013年1月一2015年2月收治的100例疱疹性咽峡炎患儿，随机分为观察组和对照组各50例，对照组单纯使用单磷酸阿糖胞昔注射液治疗，观察组在对照组的基础上加用开喉剑喷雾剂进行雾化吸入治疗，对比分析两组患儿治疗的总有效率、临床症状的消失时间、CD4+、CD8+、CD4+/CD8+、白介素「0(IL-10)、g■干扰素(IFN-g)的水平。结果：观察组患儿治疗的总有效率为94.00%,明显高
2、于对照组的72.00%(P<0.01)；观察组患儿的咽痛、疱疹、溃疡和发烧等临床症状消失时间和IFN-g.CD8+水平均明显短或低于对照组(P<0.01),而IL-10>CD4+、CD4+/CD8+水平则明显高于对照组(PvO.01)；结论：单磷酸阿糖腺昔联合开喉剑喷雾剂治疗疱疹性咽峡炎患儿，能有效提高患儿的IL-10、CD4+、CD4+/CD8+水平，降低患儿的IFN・g、CD8+水平，提高患儿的免疫水平，改善其临床症状，效果明显优于单用单磷酸阿糖腺昔。关键词单磷酸阿糖腺昔开喉剑喷雾剂临床症状免疫水平中图分类号:R286；R512.5文
3、献标识码:B文章编号:>>■1006-1533(2016)21-0033-03EffectofvidarabinemonophosphatecombinedwithKaihoujiansprayinthetreatmentof50casesofpatientswithherpangina*GONGLilin(ThePeople,sHospitalofFengcheng,Fengcheng331100,China)ABSTRACTObjective:Toobserveandevaluatetheeffectofvidarabinemonop
4、hosphatecombinedwithkaihoujiansprayinthetreatmentofpatientswithherpangina.Methods:Onehundredcasesofpatientswithherpanginawererandomlyselectedanddividedintoanobservationgroupandacontrolgroupwith50caseseach.Thecontrolgroupwastreatedwithvidarabinemonophosphatewhiletheobserva
5、tiongroupwithKaihoujianspraybesidesvidarabinemonophosphate.Thetotalefficiency,thetimeforthedisappearaneeofclinicalsymptomsandthelevelsofCD4+,CD8+,CD4+/CD8+,interleukin-10(IL-10)andhumang・interferon(IFN-g)werecompared.Results：Thetotaleffectiveratewassignificantlyhigherinth
6、eobservationgroupthaninthecontrolgroup(94%vs72%)(P<0.01).Thetimeforthedisappearaneeofclinicalsymptomssuchassorethroat,herpes,ulcerandfeverandthelevelsofIFN-gandCD8+weresignificantlyshorterorlowerintheobservationgroupthaninthecontrolgroup(P<0.01)whilethelevelsofIL-10,CD4+a
7、ndCD4+/CD8+weresignificantlyhigherintheobservationgroupthaninthecontrolgroup(P<0.01).Conclusion:VidarabinemonophosphatecombinedwithKaihoujiansprayforthetreatmentofpatientswithherpanginacaneffectivelyincreasethelevelsofIL-10,CD4+andCD4+/CD8+,reducethelevelsofCD8+andIFN-g,i
8、mprovetheimmunelevelandclinicalsymptomsofpatients,anditsclinicalefficacyissignificantlybettertha
